Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
combination therapy
Pharma
FDA rejects Elevar, Hengrui's PD-1 combo
Elevar and Hengrui's camrelizumab continues the struggle China-made PD-1s have experienced with the FDA.
Angus Liu
May 17, 2024 10:16am
AACR: Detailed data spark hope for Merck combo in NSCLC
Apr 9, 2024 1:16pm
BMS shoots for 1L liver cancer again with Opdivo, Yervoy combo
Mar 20, 2024 10:18am
AZ, GSK make case for broad I-O uses in endometrial cancer
Mar 18, 2024 11:05am
BMS, overshadowed by ADC rival, wins FDA nod in 1L bladder cancer
Mar 8, 2024 9:56am
As Imbruvica fails, Brukinsa wins FDA nod in follicular lymphoma
Mar 7, 2024 4:08pm